Is Cytokinetics, Incorporated (CYTK) a Buy, Sell, or Hold?
Cytokinetics, Incorporated
NASDAQ:CYTK
$81.93 USD
-$0.31 (-0.38%)
- Volume
- 1.44M
- Average Volume
- 2.62M
- Market Capitalization
- $10.19B
- P/E Ratio
- -12.00
- Dividend Yield
- 0.00%
- Price Target
- $108.00
- Year High
- $88.31
- Year Low
- $32.89
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.21
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Robert I. Blum |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CYTK |
| CUSIP | 23282W605 |
| CIK | 0001061983 |
| Web | https://www.cytokinetics.com |
| Phone | 650 624 3000 |
| Currency | USD |
| Employees | 673 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.56 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.21 |
| Quick Ratio | 4.21 |
| Cash Ratio | 0.65 |
Sales & Book Value
| Annual Sales | $88.04M |
| Price / Sales | 96.35 |
| Cash Flow | -4.45 |
| Price / Cash Flow | -18.57 |
| Price / Book | -12.22 |
Price Target and Rating
| Average Stock Price Forecast | $108.00 |
| High Stock Price Forecast | $140.00 |
| Low Stock Price Forecast | $84.00 |
| Forecast Upside/Downside | -24.14% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 35 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-6.54 |
| Trailing P/E Ratio | -12.00 |
| PEG Ratio | 0.44 |
| P/E Growth | 0.44 |
| Net Income | $-784.96M |
| Net Margin | -784.02% |
| Pretax Margin | -784.02% |
| Return on Equity | 139.66% |
| Return on Assets | -65.15% |
Financials Score
| AltmanZ Score | -2.38 |
| Piotroski Score | 3.00 |
| Working Capital | 640.28M |
| Total Assets | 1.27B |
| Ebit | -745.69M |
| Market Cap | 10.23B |
| Total Liabilities | 2.1B |
Poll Results
About Cytokinetics, Incorporated (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with he ... art failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
2026-07-14 17:20:21
The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity holdings.
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
2026-07-10 15:11:07
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?
2026-07-07 07:40:01
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
2026-07-07 07:30:00
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
2026-06-26 14:40:22
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
2026-06-25 08:15:12
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-17 16:00:00
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whose employment commenced in May and June, 2026, as a material inducement to their employment.
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
2026-06-17 11:56:04
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
Frequently Asked Questions
-
What is the current Cytokinetics, Incorporated (CYTK) stock price?
-
Cytokinetics, Incorporated(NASDAQ:CYTK) stock price is $81.93 in the last trading session. During the trading session, CYTK stock reached the peak price of $88.31 while $32.89 was the lowest point it dropped to. The percentage change in CYTK stock occurred in the recent session was --0.38% while the dollar amount for the price change in CYTK stock was -$-0.31.
-
CYTK's industry and sector of operation?
-
The NASDAQ listed CYTK is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYTK?
-
James A. Spudich | Co-Founder & Member of Scientific Advisory Board
James H. Sabry | Co-Founder & Chairman of Scientific Advisory Board
Jeff Lotz | Vice President of Sales & Operations
Fady Ibraham Malik FACC | Executive Vice President of Research & Development
Holly Laughlin | Vice President of Accounting & Corporate Controller -
How many employees does CYTK have?
-
Number of CYTK employees currently stands at 673. CYTK operates from 350 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for CYTK official website?
-
Official Website of CYTK is: https://www.cytokinetics.com
-
How do I contact CYTK?
-
CYTK could be contacted at phone #650 624 3000 and can also be accessed through its website. CYTK operates from 350 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of CYTK are traded daily?
-
The average number of CYTK shares traded daily for last 3 months was 2.62M.
-
What is the market cap of CYTK currently?
-
The market value of CYTK currently stands at $10.19B with its latest stock price at $81.93